Vasoseal hemostasis following coronary interventions with Abciximab

Lunney, L; Karim, Kazi Mohammad Monwarul; Little, Thomas

doi:10.1002/(sici)1097-0304(199808)44:4<405::aid-ccd7>3.3.co;2-p

Cathet. Cardiovasc. Diagn.

1998

DOI: 10.1002/(sici)1097-0304(199808)44:4<405::aid-ccd7>3.3.co;2-p

|View full text |Cite

Vasoseal hemostasis following coronary interventions with Abciximab

L Lunney

Kazi Mohammad Monwarul Karim²,

Thomas Little³

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

1999

2003

Publication Types

Select...

Article4

Relationship

Self Cite0

Independent4

Authors

Journals

Cited by 4 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Independent of their various concepts (col[agen plug, intra-arterial anchor/collagen combination, thrombin/collagen procoagulant or vascular suture), all sealing devices have shown to significantly reduce time to hemostasis [1,2,8,12,14,[17][18][19][20][21]25]. Independent of their various concepts (col[agen plug, intra-arterial anchor/collagen combination, thrombin/collagen procoagulant or vascular suture), all sealing devices have shown to significantly reduce time to hemostasis [1,2,8,12,14,[17][18][19][20][21]25].…”

mentioning

confidence: 99%

Final report of the European multi-center registry using the Deutt™ vascular sealing device

Silber¹,

Tofte

Kjellevand

et al. 1999

Herz

View full text Add to dashboard Cite

Duett, a novel vascular sealing device, was first clinically used in July 1997. A European multi-center registry was established to evaluate the safety and procedural success of the Duett sealing device in a broad range of patients undergoing diagnostic or interventional endovascular procedures. At 25 European sites 1587 patients were enrolled. All patients (> or = 18 years) must have given informed consent for the use of the sealing device after a diagnostic and/or interventional endovascular procedure performed via a femoral arterial approach. Standard length (< or = 10 cm) 5 to 9 F introducer sheaths had to be used. An ACT of < or = 400 s, and any approved GP IIb/IIIa platelet receptor antagonist was permitted. Successful deployment could be achieved in 96.2% (1526/1587 patients) with complete hemostasis within 2 to 5 minutes in over 95% of the patients. The complication-free rate was 96.4%. Arterial occlusions were rare (4 patients) and successfully treated with surgical repair in 1 and with thrombolysis in 3 patients. Pseudoaneurysms occurred in 34 patients, the majority (30/34) were successfully treated with ultrasound-guided compression or resolved spontaneously. The total rate of major complications was 2.6% (41/1587). The final results of the European registry demonstrate that the Duett sealing device can be used with a high procedural success following diagnostic and interventional endovascular procedures. The incidence of major complications is low and comparable to all other approved vascular closure devices and manual compression. CE-mark certification was approved at the end of 1998.

show abstract

mentioning

confidence: 99%

Final report of the European multi-center registry using the Deutt™ vascular sealing device

Silber¹,

Tofte

Kjellevand

et al. 1999

Herz

View full text Add to dashboard Cite

show abstract

Safety of femoral closure devices after percutaneous coronary interventions in the era of glycoprotein IIb/IIIa platelet blockade

Cura

Kapadia

L’Allier

et al. 2000

The American Journal of Cardiology

View full text Add to dashboard Cite

A novel vascular sealing device for closure of percutaneous arterial access sites

Silber

Gershony

Schön

et al. 1999

The American Journal of Cardiology

View full text Add to dashboard Cite

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Vasoseal hemostasis following coronary interventions with Abciximab

Cited by 4 publications

References 0 publications

Final report of the European multi-center registry using the Deutt™ vascular sealing device

Final report of the European multi-center registry using the Deutt™ vascular sealing device

Safety of femoral closure devices after percutaneous coronary interventions in the era of glycoprotein IIb/IIIa platelet blockade

A novel vascular sealing device for closure of percutaneous arterial access sites

Contact Info

Product

Resources

About